Reported about 11 hours ago
Eli Lilly shares fell over 6% following a disappointing revenue forecast for Q4 2024, which was revised down to $13.5 billion, missing Wall Street's $14 billion expectation. Although this represents a 45% increase from the previous year, analysts were surprised by the downward revision amidst a 45% growth in the US incretin market. Lilly also anticipates its major diabetes and weight-loss products to underperform, yet some experts remain optimistic about future financial performance and pipeline developments.
Source: YAHOO